Teva Pharmaceutical Industries Limited Announces Launch Of Generic Baraclude® Tablets, 0.5mg And 1mg, In The United States

JERUSALEM--(BUSINESS WIRE)--Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) today announces the launch of the generic equivalent to Baraclude® (Entecavir) Tablets, 0.5mg and 1mg, in the United States. Teva was first to file, making the product eligible for 180 days of marketing exclusivity.

Baraclude® (Entecavir) Tablets, 0.5mg and 1mg, marketed by Bristol-Myers Squibb, had annual sales of approximately $328 million in the United States, according to IMS data as of June 2014.

Hey, check out all the research scientist jobs. Post your resume today!